Long-term outcomes of rituximab therapy in pemphigus
Long-term outcomes of rituximab therapy in pemphigus
复制标题
DOI：
10.1111/jdv.16561
复制
发表时间：
2020-07-09
影响因子：
9.2
通讯作者：
Hammers, C. M.
中科院分区：
文献类型：
--
作者：
Shimanovich, I;Baumann, T.;Hammers, C. M.
目的探讨利妥昔单抗治疗天疱疮的远期疗效。方法回顾性分析59例天疱疮患者用利妥昔单抗治疗，中位观察时间为104个月。结果利妥昔单抗治疗第1个周期后完全缓解率（CRoff）为39%，增加额外的利妥昔单抗疗程后增加至61%。27%的患者实现了长期CRoff。第一个利妥昔单抗周期后的复发率为63%，随后的利妥昔单抗周期降至约40%。第一个和随后的利妥昔单抗周期后复发的中位时间为25个月。重新利妥昔单抗治疗在94%的病例中重新获得完全缓解。基线抗桥粒芯糖蛋白抗体水平
Background Rituximab induces a rapid remission in most patients with pemphigus.Objective Our aim was to assess the long-term efficacy of rituximab in this disease.Method We conducted a retrospective study of 59 patients with pemphigus treated with rituximab and observed over a median period of 104 months.Results The rate of complete remission off therapy (CRoff) after the first rituximab cycle was 39%, increasing to 61% with additional rituximab courses. Long-term CRoff was achieved in 27% of patients. The recurrence rate after the first rituximab cycle was 63%, decreasing to approximately 40% with subsequent rituximab cycles. Median time to relapse after the first and subsequent rituximab cycles was 25 months. Renewed rituximab therapy reinduced complete remission in 94% of cases. Baseline anti-desmoglein antibody levels of